DAX23.516 -1,1%ESt505.290 -1,3%Top 10 Crypto13,50 -3,0%Dow42.198 -1,8%Nas19.407 -1,3%Bitcoin91.190 -0,7%Euro1,1547 ±0,0%Öl75,18 +6,9%Gold3.433 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 NVIDIA 918422 BYD A0M4W9 CureVac A2P71U Lufthansa 823212 BioNTech (ADRs) A2PSR2 HENSOLDT HAG000 Tesla A1CX3T Deutsche Telekom 555750 Novo Nordisk A3EU6F Bayer BAY001 TUI TUAG50 Siemens Energy ENER6Y Boeing 850471
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht tiefrot ins Wochenende -- Wall Street letztlich im Minus -- Ölpreise im Höhenflug -- Goldalternative: Silberpreis schießt auf 13-Jahreshoch -- Arista Networks, Lufthansa im Fokus
Top News
Die Highlights im TecDAX: Gewinner und Verlierer der KW 24 im Überblick Die Highlights im TecDAX: Gewinner und Verlierer der KW 24 im Überblick
Goldpreis, Ölpreis & Co. - Das waren die Tops und Flops der Rohstoffe in KW 24 Goldpreis, Ölpreis & Co. - Das waren die Tops und Flops der Rohstoffe in KW 24
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Novo Nordisk Aktie

Handeln
Aktien-Sparplan anlegen
68,87 EUR -1,03 EUR -1,47 %
STU
69,27 EUR -0,11 EUR -0,16 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.309,42 Mrd. EUR

KGV27,53Div. Rendite1,83%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3EU6F

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINDK0062498333

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNONOF

Novo Nordisk Aktien News

DatumMeistgelesen
GlobeNewswireNovo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
GlobeNewswireADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care
GlobeNewswireNovo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
Wer­bungNovo Nordisk-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireNovo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
GlobeNewswireNovo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
GlobeNewswireNovo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presente
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
GlobeNewswireNovo Nordisk announces changes in Executive Management
GlobeNewswireNovo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
GlobeNewswireOzempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
GlobeNewswireResolutions from the Annual General Meeting of Novo Nordisk A/S
GlobeNewswireThe United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
GlobeNewswireNovo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
GlobeNewswireNovo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
GlobeNewswireNovo Nordisk files annual report with the SEC
GlobeNewswireNovo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireValo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
GlobeNewswireThe acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
GlobeNewswireNovo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
GlobeNewswireNovo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireThe European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk News

Novo Nordisk News: auf dieser Seite finden Sie alle Novo Nordisk News und Nachrichten zur Novo Nordisk Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.